← Leaderboards
Isaac Eliaz
Eliaz Therapeutics, Inc.
$1,906,548
Attributed
$1,906,548
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $990.8K · FY2018–23$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,906,548 · 2
By mechanism
R44$1,681,971 · 1
R43$224,577 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Effective Therapy”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$69,114,853
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Yunda Huang · Fred Hutchinson Cancer Center$51,679,442
Research focus
Effective TherapyImmune ActivationCutaneousEffectivenessFibrosisImmuneCecal Ligation PunctureCommunicationBlood Component RemovalDevicesChronic DiseaseFamily SuidaeGalectin 3HistologicAutomobile DrivingAffinityAcute DiseaseCommercializationBiological MarkersAcute Renal Failure With Renal Papillary NecrosisBloodCytokineAcuteIncidence
Grant awards (3)
Depleting Circulating Galectin-3 with Therapeutic Apheresis: A NovelTreatment for Sepsis/AKI$990,810
R44 · FY2023 · GM · contact PI
Depleting Circulating Galectin-3 with Therapeutic Apheresis: A NovelTreatment for Sepsis/AKI$691,161
R44 · FY2022 · GM · contact PI
Depleting Circulating Galectin-3 with Therapeutic Apheresis: A Novel Treatment for Sepsis/AKI.$224,577
R43 · FY2018 · GM · contact PI